Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Greece
Greece- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
39 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Greece
Greece- Participants:18–64 years
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:Greece
Greece- Participants:18–64 years · 65+ years
Recruiting
Atrial fibrillation
RecruitingInvestigational
Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation
Investigational
- Disease:Atrial fibrillation
- Substances:Abelacimab
Countries:Greece
Greece- Participants:65+ years
- Substances:Abelacimab
Recruiting
Bladder cancer
RecruitingRegistered drugNo placebo
A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer
Registered drugNo placebo
- Disease:Bladder cancer
- Substances:DocetaxelPaclitaxel+2
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Docetaxel
Recruiting
Squamous cell carcinoma of lung+4
RecruitingRegistered drug
A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer
Registered drug
- Disease:Squamous cell carcinoma of lungNon-small cell lung cancer+3
- Substances:CarboplatinPaclitaxel+4
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Malignant melanoma
RecruitingRegistered drugNo placebo
A Study Comparing MB11 and Nivolumab in Adults With Previously Untreated Advanced or Metastatic Melanoma
Registered drugNo placebo
- Disease:Malignant melanoma
- Substances:Nivolumab
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Nivolumab
Recruiting
Non-small cell lung cancer+1
RecruitingRegistered drugNo placebo
A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation
Registered drugNo placebo
- Disease:Non-small cell lung cancerLung neoplasm malignant
- Substances:CarboplatinCisplatin+3
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Investigational
Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists
Investigational
- Substances:Finerenone
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Finerenone
Recruiting
Non-small cell lung cancer
RecruitingRegistered drugNo placebo
Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:PembrolizumabSIGVOTATUG VEDOTIN
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Hormone-refractory prostate cancer+1
RecruitingRegistered drugNo placebo
Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy
Registered drugNo placebo
- Disease:Hormone-refractory prostate cancerProstate cancer metastatic
- Substances:Codeine PhosphateDocetaxel+5
Countries:Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Codeine Phosphate